Voleon Capital Management LP Takes $624,000 Position in Dyne Therapeutics, Inc. $DYN

Key Points

• Voleon Capital Management LP acquired 59,673 shares of Dyne Therapeutics valued at approximately $624,000, representing 0.05% of the company.
• Analyst ratings vary, with a consensus of “Buy” and an average target price of $34.07, despite several analysts lowering their target prices recently.
• Dyne Therapeutics reported a quarterly loss of ($0.97) EPS, beating expectations slightly, and has a market cap of $1.88 billion with its stock currently priced at $13.25.

Voleon Capital Management LP acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 59,673 shares of the company's stock, valued at approximately $624,000. Voleon Capital Management LP owned approximately 0.05% of Dyne Therapeutics as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Northern Trust Corp raised its position in Dyne Therapeutics by 7.7% in the 4th quarter. Northern Trust Corp now owns 777,013 shares of the company's stock worth $18,306,000 after purchasing an additional 55,511 shares during the period. Comerica Bank raised its position in Dyne Therapeutics by 20,133.7% in the 4th quarter. Comerica Bank now owns 35,409 shares of the company's stock worth $834,000 after purchasing an additional 35,234 shares during the period. Ameriprise Financial Inc. raised its position in Dyne Therapeutics by 3.2% in the 4th quarter. Ameriprise Financial Inc. now owns 219,635 shares of the company's stock worth $5,175,000 after purchasing an additional 6,735 shares during the period. BNP Paribas Financial Markets purchased a new position in Dyne Therapeutics in the 4th quarter worth $1,578,000. Finally, D. E. Shaw & Co. Inc. raised its position in Dyne Therapeutics by 83.1% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 133,772 shares of the company's stock worth $3,152,000 after purchasing an additional 60,732 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Stock Down 2.3%

Shares of Dyne Therapeutics stock traded down $0.31 on Monday, reaching $12.84. The company's stock had a trading volume of 259,689 shares, compared to its average volume of 2,595,237. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -3.33 and a beta of 1.10. The firm's fifty day simple moving average is $11.21 and its two-hundred day simple moving average is $11.11. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $37.08. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02. Equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, CEO John Cox acquired 100,000 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was purchased at an average cost of $9.11 per share, with a total value of $911,000.00. Following the completion of the acquisition, the chief executive officer directly owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 20.77% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Raymond James Financial upgraded shares of Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their target price for the stock from $31.00 to $35.00 in a research report on Monday, August 25th. JPMorgan Chase & Co. decreased their price objective on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Jones Trading started coverage on shares of Dyne Therapeutics in a research report on Thursday, June 26th. They issued a "buy" rating and a $30.00 price objective on the stock. Guggenheim restated a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, June 18th. Finally, Robert W. Baird cut their target price on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 18th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of "Buy" and an average price target of $34.07.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.